Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 8/20 | 0.47 |
| ▸ | ACE | P12821 | 3/20 | 0.45 |
| ▸ | NR1D1 | P20393 | 4/20 | 0.44 |
| ▸ | BAD | Q92934 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17559495 | 1.00 | BCL2 (0.47) | BCL2ACENR1D1BADPOLB | |
| SCHEMBL17559498 | 1.00 | BCL2 (0.47) | BCL2ACENR1D1BADPOLB | |
| SCHEMBL5064885 | 0.87 | ACE (0.43) | BCL2ACENR1D1POLBTDP1 | |
| SCHEMBL14163272 | 0.86 | BCL2 (0.49) | BCL2NR1D1BAD | |
| SCHEMBL14067129 | 0.85 | OPRM1 (0.54) | BCL2ACEBADTDP1 | |
| SCHEMBL15675696 | 0.85 | OPRM1 (0.54) | BCL2ACEBADTDP1 | |
| SCHEMBL20738536 | 0.85 | OPRM1 (0.54) | BCL2ACEBADTDP1 | |
| SCHEMBL4783225 | 0.85 | OPRM1 (0.53) | BCL2ACENR1D1BAD | |
| SCHEMBL24925815 | 0.83 | BCL2 (0.44) | BCL2ACENR1D1BADPOLB | |
| SCHEMBL17838137 | 0.83 | OPRM1 (0.43) | BCL2ACENR1D1BADPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586170-B | Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative | 江苏集萃分子工程研究院有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117642157-A | Compounds having ((3-nitrophenyl) sulfonyl) acetamide as BCL-2 inhibitors | 伊尔治疗学股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117586170-A | Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative | 江苏集萃分子工程研究院有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20240043424-A1 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-4308092-A1 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2023161317-A1 | 5-[7-(3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBONYL)-1,2,3,4 TETRAHYDROISOQUINOLIN-6-Y L]-1H-PYRROLE-3-CARBOXAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2023-08-31 | — | — | WO | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20210290631-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2021-09-23 | — | — | US | disclosed |
| US-11058689-B2 | Pyrrole compounds, a process for their preparation and pharmaceutical | LES LABORATOIRES SERVIER (FR) | 2021-07-13 | — | — | US | disclosed |
| US-20160194304-A1 | ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2016-07-07 | — | — | US | disclosed |
| US-20160152599-A1 | INDOLE AND PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2016-06-02 | — | — | US | disclosed |
| WO-2016034673-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
| US-20150313907-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2015-11-05 | — | — | US | disclosed |
| US-9108983-B2 | Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2015-08-18 | — | — | US | disclosed |
| US-20150031673-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2015-01-29 | — | — | US | disclosed |
| EP-2829539-A1 | New pyrrole derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2015-01-28 | — | — | EP | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| EP-1874768-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113837-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058689-B2 | Pyrrole compounds, a process for their preparation and pharmaceutical | PDCD11, RRM2B, RRS1 | BCL2 33/4885ACE 2275/4885NR1D1 853/4885 |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | BCL2 1/4885ACE 320/4885NR1D1 3262/4885 |
| US-20210290631-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDCD11, RRM2, RRM2B | BCL2 23/4885ACE 2437/4885NR1D1 992/4885 |
| US-20150031673-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDCD11, RRM2B, RRM2 | BCL2 20/4885ACE 2379/4885NR1D1 560/4885 |
| US-20160194304-A1 | ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RECQL, UQCRB, IRF3 | BCL2 13/4885ACE 3017/4885NR1D1 259/4885 |
| US-20240043424-A1 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | BCL2, BCL2A1, BCL2L1 | BCL2 1/4885ACE 320/4885NR1D1 3262/4885 |
| US-20160152599-A1 | INDOLE AND PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDO1, IDO2, NFATC1 | BCL2 17/4885ACE 2466/4885NR1D1 1140/4885 |
| US-20150313907-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDCD11, RRM2B, RRM2 | BCL2 20/4885ACE 2379/4885NR1D1 560/4885 |
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | BCL2 766/4885ACE 4185/4885NR1D1 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.